PATENT LICENSE AND SETTLEMENT AGREEMENT
This Patent License and Settlement Agreement ("AGREEMENT") is made as of March
4, 2004 ("EFFECTIVE DATE") by and between the following: (a) Lumenis Inc., a
Massachusetts corporation with its principal place of business in Santa Clara,
California, and Lumenis Ltd., an Israeli corporation with its principal place of
business in Yokneam, Israel (together with their parents, subsidiaries,
Affiliates, predecessors, permitted successors and assigns, collectively
"LICENSOR"); and (b) Syneron, Inc., a Delaware corporation with its principal
place of business in Toronto, Canada, and Syneron Medical Ltd., an Israeli
corporation with its principal place of business in Yokneam, Illit., Israel
(together with their parents, subsidiaries, Affiliates, predecessors, and
permitted successors and assigns, collectively "LICENSEE"). Licensor and
Licensee are each referred to herein as a "PARTY" and collectively as the
"PARTIES."
RECITALS
WHEREAS, the Parties have been involved in litigation concerning, among other
things, the alleged infringement by Licensee of certain patents owned by
Licensor and various claims and cross-claims for unfair competition, trade
disparagement and misappropriation of trade secrets, including in LUMENIS LTD.
V. SYNERON MEDICAL LTD., Case No. 02-8269 ABC (PLAx), pending as of the
Effective Date in the United States District Court for the Central District of
California (the "LOS ANGELES ACTION"); LUMENIS INC. V. SYNERON INC., Case No. CV
811282, pending as of the Effective Date in the Superior Court of the State of
California for the County of Santa Xxxxx (the "SANTA XXXXX ACTION"), and LUMENIS
LTD. X. XXXXXXXX, Case No. 2133/02, pending as of the Effective Date in district
court in Tel Aviv, Israel (the "ISRAEL ACTION") (collectively, the "PENDING
LITIGATION"); and
WHEREAS, Licensee and Licensor wishing to avoid the expense of further
litigation, have agreed to settle such Pending Litigation pursuant to the terms
set forth below without any Party making any admission of any liability, and as
part of the settlement, Licensor has agreed, among other things, to grant to
Licensee certain licenses, releases, and immunities from suit with respect to
certain patents, and Licensee has agreed to grant Licensor certain releases and
immunities from suit with respect to the Pending Litigation.
NOW, THEREFORE, in consideration of the mutual covenants, representations,
warranties and other terms and conditions contained herein, the sufficiency of
which is hereby acknowledged, the Parties hereto agree as follows:
AGREEMENT
1. DEFINITIONS
In addition to other terms defined elsewhere herein, the following terms, as
used in this Agreement, shall have the meanings indicated:
1.1 "AFFILIATE" shall mean, as to any person, any corporation, firm,
partnership, entity or other person that, directly or indirectly, controls, is
controlled by, or is under common control with such person, where "control" of a
person means the capacity to designate, appoint or otherwise determine the board
of directors or other governing authority of such person, whether by law or in
fact, and whether by (i) ownership of more than fifty percent (50%) of the
equity or rights or shares in profits and losses (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) of such person, (ii) voting rights or management
contract or agreement, (iii) any other contract or agreement that grants to any
other person effective control over the affairs and activities of such person,
or (iv) some combination of the foregoing.
1.2 "LUMENIS COMPETITORS" shall mean those persons listed on EXHIBIT F
and their respective Affiliates, successors, assigns, and controlling
shareholders.
1.3 "NET SALES" shall mean the gross revenues actually received for
the benefit of Licensee from the Sale of any products (including, without
limitation, systems, components, software, upgrades and accessories) to a third
party, less (a) normal and customary cash rebates; (b) sales, use and/or other
excise taxes or duties; (c) insurance costs and outbound transportation charges
(which include packaging and packing costs); (d) import and/or export duties;
and (e) amounts allowed in cash or credited in cash due to returns (not to
exceed the original billing or
1
CONFIDENTIAL
invoice amount). Licensee shall be deemed to have received as gross revenues the
average selling price for a product in the territory in which it is Sold in
connection with any Sale of products that does not consist solely of monetary
consideration, provided, however, that transfers of product at cost or less than
cost for bona fide research, experimental, demonstration, or trial use,
including, without limitation, for use in connection with clinical trials or
research or to obtain regulatory approvals, shall not be considered Sales of
product.
1.4 "PATENT RIGHTS" shall mean:
(a) the patents asserted in the Los Angeles Action, their
continuations, continuations in part, divisionals, revisions, extensions,
reissued and reexamined patents and patent applications, whether previously
filed or filed in the future, all patents and patent applications from which the
patents asserted in the Los Angeles Action claim priority, in whole or in part,
directly or indirectly, and all foreign counterpart patents and patent
applications of the patents and applications described herein, whether
previously filed or filed in the future, together with all patents or patent
applications anywhere in the world, whether previously filed or filed in the
future, which claim priority, in whole or in part directly or indirectly, from
any of the foregoing patents or patent applications; and
(b) all patents and patent applications anywhere in the world
that are owned by or assigned to Lumenis, or that Lumenis has the right to
license to others, involving or relating to incoherent light or gel for
therapeutic, medical, dermatological or aesthetic applications, that were filed
on or before the Effective Date, and their continuations, continuations-in-part,
divisionals, reissues, revisions, extensions and reexamination patents and
patent applications, whether previously filed or filed in the future, and all
foreign counterpart patents and patent applications of the patents and
applications described herein, whether previously filed or filed in the future,
together with all patents and patent applications anywhere in the world, whether
previously filed or filed in the future, that are owned by or assigned to
Lumenis, or that Lumenis has the right to license to others, which claim
priority, in whole or in part, directly or indirectly, from any of the foregoing
patents or patent applications;
including, without limitation, the patents and patent applications set forth in
EXHIBIT A ("SCHEDULED PATENTS") and, to the extent Licensor has any rights
therein, their continuations, continuations in part, divisionals, revisions,
extensions, reissued and reexamined patents and patent applications, whether
previously filed or filed in the future, all patents and patent applications
from which any of the Scheduled Patents claim priority, in whole or in part,
directly or indirectly, and all foreign counterpart patents and patent
applications of any of the foregoing, whether previously filed or filed in the
future, together with all patents or patent applications anywhere in the world,
whether previously filed or filed in the future, which claim priority, in whole
or in part directly or indirectly, from any of the foregoing patents or patent
applications.
1.5 "SALE" or "SELL" or "SOLD" shall mean the transfer or disposition
of a product for value by Licensee to a person other than Licensee.
1.6 "SPECIALLY COVERED PRODUCT" shall mean any product, as of the
Assignment Date (as defined in Section 9.5): (i) that Licensee had offered for
sale, is offering for sale, or (ii) in respect of which Licensee has filed with
the Food and Drug Administration a Section 510(k) Premarket Notification or a
Section 515 Premarket Approval; and any successors or follow-ons to such
products that do not in any manner incorporate technology or processes developed
by Assignee (as defined in Section 9.5) or of which Assignee is the source; and
any apparatus used to manufacture (including develop, assemble, test, repair or
maintain) any such product.
2. RELEASES AND SETTLEMENT
2.1 MUTUAL RELEASE. Each Party, on behalf of itself and its parents,
subsidiaries, Affiliates, agents, representatives, officers, directors,
shareholders, employees, attorneys, advisors, insurers, licensees, sublicensees,
successors, assigns, and heirs ("ASSOCIATED PARTIES"), hereby irrevocably
releases and forever discharges each other Party and its parents, subsidiaries,
Affiliates, agents, representatives, officers, directors, shareholders,
employees, attorneys, advisors, insurers, direct and indirect third-party
manufacturers, suppliers, distributors, resellers, sales agents, customers,
users, and licensees (such directly and indirectly related persons, the
"COMMERCIAL PARTNERS"), successors, assigns, and heirs (including, without
limitation, all persons named as defendants in the Pending Litigation) of and
from any and all claims, counterclaims, demands, actions, causes of action,
damages, liabilities, losses, payments, obligations, costs and expenses
(including, without limitation, attorneys' fees and costs) of any
2
CONFIDENTIAL
kind or nature, past, present or future, fixed or contingent, direct or
indirect, in law or equity, several or otherwise, known or unknown, suspected or
unsuspected, that arise from or relate in any way to any act or omission prior
to the Effective Date with respect to the Patent Rights or the subject matter of
the Pending Litigation, or that were or could have been brought in the Pending
Litigation ("RELEASED CLAIMS"). The foregoing release is expressly intended to
cover and include, without limitation, all claims, past, present or future,
known or unknown, suspected or unsuspected, which can or may ever be asserted by
successors, assigns, heirs, or otherwise, as the result of the matters herein
released, or the effects or consequences thereof. With respect to Licensee's
Commercial Partners, the foregoing release by Licensor and its Associated
Parties shall apply only to Released Claims arising from or relating in any way
to products or services provided by, for, or to Licensee. With respect to
Licensor's Commercial Partners, the foregoing release by Licensee and its
Associated Parties shall apply only to Released Claims arising from or relating
in any way to products or services provided by, for, or to Licensor. The
foregoing release shall not apply to each Party's obligations required to be
performed under this Agreement.
2.2 WAIVER. Each Party, on behalf of itself and its parents,
subsidiaries, Affiliates, agents, representatives, officers, directors,
shareholders, employees, attorneys, advisors, insurers, licensees, sublicensees,
successors, assigns, and heirs, hereby irrevocably and forever waives all rights
it may have arising under California Civil Code Section 1542 (or any analogous
requirement of law) with respect to the foregoing release. Each Party
understands that Section 1542 provides that:
A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of
executing the release, which if known by him must have materially
affected his settlement with the debtor.
Each Party acknowledges that it has been fully informed by its counsel
concerning the effect and import of this Agreement under California Civil Code
Section 1542 and other requirements of law.
2.3 DISMISSAL OF PENDING LITIGATION. Within ten (10) days after the
Effective Date, the parties shall cause to be completed, executed and filed with
the applicable courts stipulated dismissals with prejudice of the Pending
Litigation consistent with this Agreement and in the forms attached hereto as
EXHIBIT B (for the Los Angeles Action), EXHIBIT C (for the Santa Xxxxx Action),
and EXHIBIT D (for the Israel Action) (the "DISMISSALS").
2.4 NO DISPARAGEMENT. Neither Licensee nor Licensor, nor their
respective agents, representatives, officers, directors, employees, attorneys,
advisors, licensees, sublicensees, successors, assigns, and heirs, shall make or
publish any statements in any form or through any medium, to actual or potential
customers, members of the medical community, or the public at large that
unlawfully disparages the other's products, services, business or marketing
practices, financial condition or commercial prospects. By way of example only,
neither Licensor nor Licensee shall make or publish any unlawful statement that
represents or suggests that the other's products are unsafe or will cause
significant bodily harm to either the persons who utilize the product or the
persons who receive treatment from use of the products. Nothing contained herein
shall prohibit open and fair competition between the parties.
2.5 NO ADMISSION. This Agreement is entered into in order to
compromise and settle disputed claims, without any concession or admission of
validity or invalidity or enforceability or nonenforceability of the Patent
Rights by any Party, and without any acquiescence on the part of any Party as to
the merit of any claim, defense, affirmative defense, counterclaim, liabilities
or damages related to the Patent Rights and/or the Pending Litigation. Neither
this Agreement nor any part thereof shall be, or be used as, an admission of
infringement or liability by anyone, at any time for any purpose.
2.6 ATTORNEYS' FEES AND COSTS. Each Party shall be responsible for its
own attorneys' fees and costs in connection with this Agreement and the Pending
Litigation.
2.7 CONSENTS. Concurrent with the execution of this Agreement,
Licensor shall execute and Licensee shall cause each of Xxxxx X. Xxxxxx and Xxxx
Xxxxxxxx to execute a consent and acknowledgement of the form set forth in
EXHIBIT E.
3. LICENSE GRANT
3.1 LICENSE GRANT. Subject to the terms and conditions of this
Agreement, Licensor hereby grants to Licensee a royalty-bearing (pursuant to the
terms of Section 4), worldwide, non-exclusive right and license under the Patent
Rights to make and have made, use, import, offer to sell, sell, or otherwise
exploit or dispose of any article of
3
CONFIDENTIAL
manufacture, product, service, component or matter, and to practice and have
practiced any method, process or procedure within the Patent Rights, PROVIDED
that Licensee may not exercise its "have made" and "have practiced" rights with
any Lumenis Competitors. The right and license granted in this Section 3.1 shall
be irrevocable except that such right and license shall be revoked automatically
and without further notice or action by Licensor in the event that this
Agreement is terminated pursuant to Section 5.2. Without limiting the effect of
Section 3.2, and except as expressly provided in this Section 3.1, Licensee
shall have no right of sublicense in respect of the Patent Rights.
3.2 IMMUNITY. The rights and license granted to Licensee pursuant to
Section 3.1 shall inure to the benefit of, and includes an immunity from suit
for infringement of the Licensed Patents by Licensor or licensors of Patent
Rights to Licensor, for any direct or indirect distributor, reseller, customer
or other user of products or services made, sold, or otherwise disposed of by or
for Licensee, insofar as the inventions, discoveries and information covered by
the Patent Rights may be practiced in connection with application or use of any
such product or service, whether alone or in combination with any other product,
component or service, PROVIDED, that the foregoing immunity shall not extend to
any claims by any person, including Licensor, for infringement of any patent
claim to the extent (and only to the extent) that each limitation of such patent
claim is met by such other product, component or service alone, and PROVIDED,
FURTHER, Licensee shall provide reasonably prompt notice to Licensor of any such
suit or threatened suit by licensors of Patent Rights to Licensor. Failure to
provide such notice shall relieve the indemnifying Party of its indemnity
obligations hereunder to the extent (and only to the extent) it suffered
prejudice from such failure.
4. PAYMENTS AND ROYALTIES
4.1 INITIAL LICENSE FEE. In consideration of the rights and license
granted by Licensor to Licensee under this Agreement, Licensee agrees to pay
Licensor within ten (10) days after the Effective Date an initial license fee
equal to 1.5 million United States Dollars ($1,500,000), which fee shall be
considered an advance and shall be credited against the total maximum royalties
due hereunder pursuant to Section 4.2.
4.2 RUNNING ROYALTIES. In further consideration of the rights and
license granted by Licensor to Licensee under this Agreement, except as
otherwise provided in Section 4.3, Licensee agrees to pay to Licensor a running
royalty equal to three percent (3%) of Net Sales, up to a total maximum
(including the $1,500,000 initial license fee payable pursuant to Section 4.1)
of 4.2 million United States Dollars ($4,200,000). Under no circumstances shall
the total royalties paid by Licensee to Licensor under this Agreement exceed
$4,200,000. The running royalties under this Section 4.2 for Sales of products
shall be payable only for Sales beginning on the date of the first Sale after
the Effective Date. The running royalties set forth in this Section 4.2 shall be
calculated and paid on a quarterly basis within thirty (30) days after the end
of each fiscal quarter during the term of this Agreement, with the first such
calculation and payment in respect of Net Sales for the first and second fiscal
quarters of 2004 to be performed and made no later than July 30, 2004.
4.3 LIMITATIONS ON RUNNING ROYALTIES. The running royalties in respect
of each unit of product under Section 4.2 shall be payable only with respect to
the first Sale thereof. In the event that more than one patent within the Patent
Rights is applicable to any product subject to royalties under this Section 4,
then only one royalty shall be paid to Licensor in respect of such quantity of
products and in any event duplication of the running royalty shall be avoided.
No royalty shall be payable under Section 4.2 with respect to the transfer of
products between or among Syneron, Inc., Syneron Medical Ltd., or their parents,
subsidiaries, Affiliates, predecessors, successors and assigns; nor shall a
royalty be payable under Section 4.2 with respect to Sales of products for use
in clinical trials or as samples.
4.4 PAYMENTS. All amounts payable hereunder by Licensee shall be
payable in United States Dollars. If any currency conversion shall be required
in connection with the payment of royalties hereunder, such conversion shall be
made using the exchange rates customarily used by Licensee in the preparation of
its own financial statements. Any deduction, withholding or taxes that Licensee
is required to withhold by statute or applicable law, with respect to the
amounts payable under this Agreement, shall be deducted from such amounts, and
Licensee shall furnish Licensor, at Licensor's request, with a copy of the
certificate or other documentation evidencing the payment to applicable tax
authorities of the deducted, withheld or taxed amount. Payment shall be made by
wire transfer to an account designated in writing by Licensor, without any
deduction for wire transfer or conversion fees or charges.
4
CONFIDENTIAL
4.5 PAYMENT REPORTS; RIGHT OF INSPECTION; DISPUTES.
(a) Licensee shall, concurrently with the royalty payments
provided in Section 4.2, deliver to Licensor a report setting forth: (i) the Net
Sales for that quarter, and (ii) the calculation of royalties thereon; which
report shall be certified or otherwise confirmed in writing by Syneron's chief
financial officer. A report shall be deemed accepted by Licensor, and shall be
binding on the Parties, in the event Licensor does not, within one hundred
twenty (120) days of receipt of such report, provide notice to Licensee in
writing or by email to Licensee's chief financial officer that Licensor intends
to challenge all or any part of such report, and setting forth in general terms
the nature of such challenge. Licensor shall have the right, no more than twice
each calendar year, to have a reputable audit firm in the United States or
Israel with no current or prior relationship with either Licensee or Licensor
(the "Auditor") inspect Licensee's books and records, upon reasonable notice, at
Licensee's premises, and during normal business hours, solely for the purpose of
verifying Licensee's compliance with its payment obligations to Licensor
hereunder. Any such Auditor shall be subject to Licensee's approval, such
approval not to be unreasonably withheld, provided, however, that Licensee
consents in advance to the use of PricewaterhouseCoopers as the Auditor provided
that PricewaterhouseCoopers has not been engaged by Licensor in any other
capacity between the Effective Date and the date of any such audit. Any such
Auditor shall, prior to obtaining access to Licensee's books and records, enter
into a confidentiality agreement with Licensee acceptable in form to Licensor,
such acceptance not to be unreasonably withheld, providing, among other things,
that only the Determined Amount, as defined below, may be disclosed to Licensor.
Any such audit shall be conducted in a manner so as to minimize the impact on
Licensee's ordinary operations. Licensor shall maintain and preserve its books,
records, and documents necessary to the calculation of royalties hereunder for
at least two (2) years from the date of such report, after which time, it shall
have no further obligation to maintain such books, records, and documents
(notwithstanding the provisions of subsection (b) below). Subject only to
subsection (b) below, the Auditor's determination, based on an audit as
described above, of the actual amount payable or owed (the "Determined Amount")
shall be final and binding. The Auditor shall provide Licensee and Licensor with
written notice of the Determined Amount. In the event that such inspection
reveals an underpayment by Licensee of the actual royalties owed, Licensee shall
pay to Licensor such difference, plus interest thereon at the rate of twelve
percent (12%) per annum, from the date such payment was due until the date of
actual payment to Licensor. In the event that such inspection reveals an
overpayment by Licensee, Licensor shall pay to Licensee such difference. Any
such payments shall be made within thirty (30) days of such written notice from
the Auditor to the Party responsible for such payment. The costs for such
Auditor shall be borne equally by the Parties, PROVIDED that in the event the
Determined Amount is less than eighty percent (80%) of the actual amount paid by
Licensee, then Licensor shall pay all such costs, and PROVIDED further, that if
the Determined Amount is more than one hundred twenty percent (120%) of the
actual amount paid by Licensee, then Licensee shall pay all such costs.
(b) In the event Licensor believes, in good faith, that the
Auditor is likely to have committed a bona fide error, or engaged in fraud or
misconduct, in determining the Determined Amount to the material prejudice of
Licensor, Licensor may, at its own expense, appoint its own independent,
unaffiliated auditor (which may be its regular outside auditor) to review an
Auditor's report. In such case, Licensor shall deliver written notice thereof to
the Auditor and to Licensee, setting forth the specific grounds for such review,
and Licensee agrees that in such case the Auditor shall disclose to Licensor's
auditor all information in its possession used in preparation of such report,
PROVIDED that Licensor's auditor shall have first entered into a confidentiality
agreement with the Auditor and Licensee acceptable in form to Licensee, such
acceptance not to be unreasonably withheld, providing, among other things, that
no information may be disclosed to Licensor, other than the conclusions of
Licensor's auditors with respect to the accuracy of the Determined Amount and
the reasons for any inaccuracy ("INACCURACY"). Any remaining dispute shall be
addressed as provided in Section 9.3.
5. TERM AND TERMINATION
5.1 TERM. Unless terminated earlier pursuant to this Section 5, the
term of this Agreement shall commence on the Effective Date and shall continue
in full force and effect until the later of (a) expiration, revocation or
invalidation of the last patent within the Patent Rights and (b) abandonment of
the last patent application within the Patent Rights.
5.2 TERMINATION. Licensor may terminate this Agreement upon thirty
(30) days written notice of and describing with particularity a Breach of this
Agreement by Licensee, if such Breach is not cured within such thirty (30) day
period. The following and only the following events shall be deemed "Breaches":
(a) Licensee's failure to
5
CONFIDENTIAL
deliver, when due, any report required under the first sentence of Section
4.5(a); (b) Licensee's failure to pay, when due, any royalties admitted by
Licensee to be due hereunder in any such report that remains uncorrected; and
(c) Licensee's failure to pay, when due, any Determined Amount.
5.3 EFFECT OF TERMINATION. Termination of this Agreement by Licensor
shall not act as a waiver of any breach of this Agreement and shall not act as a
release of any Party from any liability for breach of such Party's obligations
under this Agreement. Licensor shall not be liable to Licensee for damages of
any kind solely as a result of terminating this Agreement in accordance with its
terms, and termination of this Agreement by Licensor shall be without prejudice
to any other right or remedy of Licensor under this Agreement or applicable law.
5.4 SURVIVAL. Sections 1, 2, 3.2, 5.3, 6, 7, 8 (to the extent set
forth therein), and 9 shall survive the expiration and any termination of this
Agreement. Except as otherwise provided in this Section 5, all rights and
obligations of the parties under this Agreement shall terminate upon the
expiration or termination of this Agreement; PROVIDED that, upon termination of
this Agreement, nothing herein shall be construed to release any Party of any
obligation hereunder that matured or accrued prior to the effective date of such
termination.
6. REPRESENTATIONS, WARRANTIES AND COVENANTS
6.1 REPRESENTATIONS, WARRANTIES AND COVENANTS. Licensor represents,
warrants and covenants that (a) Licensor has the full power to enter into this
Agreement and to perform its obligations hereunder; (b) Licensor is the owner of
the entire right, title and interest in and to the Scheduled Patents; (c)
Licensor has the sole right and authority to enter into this Agreement and grant
the rights, licenses, releases and immunities granted hereunder, without the
need for any licenses, releases, consents, approvals or immunities not yet
granted or obtained; (d) Licensor has not previously granted and shall not grant
any rights in the Patent Rights that are inconsistent with the rights and
licenses granted to Licensee herein; (e) Licensor shall either maintain the
Patent Rights during the term of this Agreement, or, if Licensor elects not to
maintain any patent forming part of the Patent Rights, Licensor shall provide
reasonable prior notice to Licensee, and shall offer Licensee reasonable terms
for the purchase of such patent (which terms shall also include a royalty-free
license of such patent back to Licensor), and (f) Licensor has provided to
Licensee or its counsel full access, on a strictly confidential basis, to all
patents and patent applications owned by or assigned to Licensor, or to which
Licensor has any right of license or sublicense on and as of the Effective Date.
The sole remedy for breach of the representation and warranty set forth in
Section 6.1(f) shall be that any patent, patent application, or patent license
not disclosed to Licensee in breach of such representation and warranty shall
automatically be included within the Patent Rights, and Licensee shall have a
license thereto pursuant to Section 3 of this Agreement.
Licensee represents, warrants and covenants that it has the full power to enter
into this Agreement and to perform its obligations hereunder.
6.2 DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 6.1
OF THIS AGREEMENT, NO PARTY MAKES ANY OTHER REPRESENTATIONS OR WARRANTIES,
WHETHER EXPRESS OR IMPLIED.
7. INDEMNIFICATION
(a) Licensor shall hold harmless and indemnify Licensee and its parents,
subsidiaries, Affiliates, agents, representatives, officers, directors,
shareholders, employees, attorneys, advisors, insurers, direct and indirect
distributors, resellers, customers, users, and licensees, successors, assigns,
and heirs, from and against amounts paid to third parties as a result of any and
all claims, demands, causes of action, suits or proceedings whatsoever
("CLAIM(S)"), and any and all damages, liabilities, losses, settlements, costs
(including, without limitation, reasonable attorneys' fees and costs), arising
out of or relating to any such Claim, in all cases to the extent (and only to
the extent) based on any breach of (or any claim that, if true, would be a
breach of or would be inconsistent with) Licensor's representations, warranties
and covenants set forth in Section 6.1.
(b) Licensee shall hold harmless and indemnify Licensor and its parents,
subsidiaries, Affiliates, agents, representatives, officers, directors,
shareholders, employees, attorneys, advisors, insurers, direct and indirect
distributors, resellers, customers, users, and licensees, successors, assigns,
and heirs, from and against amounts paid to third parties as a result of any and
all claims, demands, causes of action, suits or proceedings whatsoever
("CLAIM(S)"), and any and all damages, liabilities, losses, settlements, costs
(including, without limitation, reasonable
6
CONFIDENTIAL
attorneys' fees and costs), arising out of or relating to any such Claim, in all
cases to the extent (and only to the extent) based on Licensee's breach of (or
any claim that, if true, would be a breach of or would be inconsistent with) its
representations, warranties and covenants set forth in Section 6.1 or based on
any defect in the manufacturing, design or operation of any devices
manufactured, modified, altered or sold by Licensee, presently, in the past or
hereafter.
(c) The non-indemnifying Party shall provide reasonably prompt notice to the
indemnifying Party of any Claim. Failure to provide such notice shall relieve
the indemnifying Party of its indemnity obligations hereunder, to the extent
(and only to the extent) it suffered prejudice from such failure.
8. CONFIDENTIAL INFORMATION
Each Party shall keep the material terms of this Agreement confidential,
provided, however, the parties may file and otherwise disclose the Dismissals
and the information contained in the mutually agreed-upon, joint press release
concerning the settlement of the Pending Litigation that was released on January
20, 2004 (the "JOINT PRESS RELEASE"). No Party may issue any other press release
or otherwise disclose any of the material terms of this Agreement to any third
party without the express written consent of the other Party. Notwithstanding
the foregoing, a Party may disclose such information (a) to the extent it is
legally compelled to do so (including as required by securities laws to the
extent such laws are or become applicable to either Party), provided that prior
to any such compelled disclosure, the Party so compelled ("DISCLOSING PARTY")
shall give the other Party ("PROTECTED PARTY") reasonable advance notice of any
such disclosure; (b) in confidence, to legal counsel; (c) in confidence, to
accountants, banks, and financing sources and their advisors; and (d) in
connection with the enforcement of this Agreement or any rights hereunder. The
confidentiality obligations of the parties pursuant to this Section shall
continue in full force and effect for a period of five (5) years after the
Effective Date.
9. GENERAL
9.1 NOTICES. Any notice, request, demand or other communication
required or permitted hereunder shall be in writing, shall reference this
Agreement and shall be deemed to be properly given: (a) when delivered
personally; (b) when sent by facsimile, with written confirmation of receipt;
(c) five (5) business days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (d) two (2) business days
after deposit with a private industry express courier, with written confirmation
of receipt. All notices shall be sent to the address set forth below (or to such
other address or person as may be designated by a Party by giving written notice
to the other Party pursuant to this Section).
To Licensor: To Licensee:
Lumenis Ltd. Syneron Medical Ltd.
Yokneam Industrial Park Industrial Xxxx
XXX # 000 Xxxxxxx Xxxxx, 00000
Yokneam 20692 X.X. Xxx 000
Xxxxxx Xxxxxx
Attn: Chief Executive Officer Attn: Chief Executive Officer
9.2 GOVERNING LAW. This Agreement shall be governed by, and construed
and interpreted in accordance with, the laws of the State of California (without
giving effect to the laws, rules or principles thereof regarding conflict of
laws); provided, however, that all questions with respect to validity of any
patents or patent applications within the Patent Rights shall be determined in
accordance with the laws of the respective country in the territory in which
such patents or patent applications shall have been granted or filed, as
applicable.
9.3 DISPUTE RESOLUTION; JURISDICTION; SERVICE; ENFORCEMENT. Any
dispute related to calculation or payment of royalties shall initially be
addressed as provided in Section 4.5. Any dispute arising out of the finding of
an Inaccuracy by Licensor's auditor pursuant to Section 4.5(b) or other dispute
in respect of this Agreement not related to the calculation of royalties shall
be addressed diligently and in good faith by the Parties. In the event such
dispute cannot be resolved within forty-five (45) days, the Parties shall agree
to a prompt meeting in person or by telephone between the parties' respective
chief financial officers, who shall thereafter consult with their respective
7
CONFIDENTIAL
chief executive officers. If the Parties are then unable to resolve such
dispute, the matter shall be submitted to non-binding mediation in a location
agreed by the Parties, or failing such agreement, in Tel Aviv, Israel. The
Parties agree that no Party may bring an action under this Agreement unless the
Parties have attended mediation in good faith, and such mediation is
unsuccessful. Each Party (a) hereby irrevocably submits itself to and consents
to the exclusive jurisdiction of the United States District Court for the
Central District of California (or if such court lacks jurisdiction, the courts
of the State of California, County of Los Angeles) for the purposes of any
action, claim, suit or proceeding in connection with any controversy, claim or
dispute arising out of or relating to this Agreement or any of Licensee's
products, and (b) hereby waives, and agrees not to assert, by way of motion, as
a defense or otherwise, in any such action, claim, suit or proceeding, any claim
that it is not personally subject to the jurisdiction of such court(s), that the
action, claim, suit or proceeding is brought in an inconvenient forum, or that
the venue of the action, claim, suit or proceeding is improper.
9.4 RELATIONSHIP OF PARTIES. Nothing contained in this Agreement shall
be deemed or construed as creating a joint venture, partnership, agency,
employment or fiduciary relationship between the parties. Neither Licensee nor
Licensor, or any of their agents, have any authority of any kind to bind the
other in any respect whatsoever, and the relationship of the parties is, and at
all times shall continue to be, that of independent contractors.
9.5 ASSIGNMENT. This Agreement may not be assigned by Licensee without
the prior written consent of Licensor. Notwithstanding the foregoing, Licensor's
consent shall not be required for any assignment to a party that succeeds to all
or substantially all of Licensee's business or assets relating to this
Agreement, whether by sale, merger, operation of law or otherwise, provided that
such assignee or transferee ("Assignee") promptly agrees in writing to be bound
by the terms and conditions of this Agreement and provided that, if such
Assignee is a Lumenis Competitor, the references to "articles of manufacture"
and "products" in the license set forth in Section 3.1 shall automatically be
amended as of the date of such assignment ("ASSIGNMENT DATE") to be references
to "Specially Covered Products." This Agreement shall be binding upon and shall
inure to the benefit of the parties and their respective permitted successors
and assigns.
9.6 FURTHER ASSURANCES. Each Party agrees to take or cause to be taken
such further actions, and to execute, deliver and file or cause to be executed,
delivered and filed such further documents and instruments, and to obtain such
consents, as may be reasonably required or requested in order to effectuate
fully the purposes, terms and conditions of this Agreement.
9.7 WAIVER. A waiver, express or implied, by either Licensor or
Licensee of any right under this Agreement or of any failure to perform or
breach hereof by the other Party hereto shall not constitute or be deemed to be
a waiver of any other right hereunder or of any other failure to perform or
breach hereof by such other Party, whether of a similar or dissimilar nature
thereto.
9.8 SEVERABILITY. If any provision of this Agreement is unenforceable
or invalid under any applicable law or is so held by applicable court decision,
such unenforceability or invalidity shall not render this Agreement
unenforceable or invalid as a whole, and, in such event, such provision shall be
changed and interpreted so as to best accomplish the objectives of the parties
within the limits of applicable law or applicable court decision.
9.9 FORCE MAJEURE. In the event any Party hereto is prevented from or
delayed in the performance of any of its obligations hereunder by reason of acts
of God, war, strikes, riots, storms, fires or any other cause whatsoever beyond
the reasonable control of the Party, the Party so prevented or delayed shall be
excused from the performance of any such obligation to the extent and during the
period of such prevention or delay.
9.10 BANKRUPTCY. All licenses, immunities, releases, and similar rights
granted under or pursuant to this Agreement by Licensor to Licensee are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code, licenses of rights of "intellectual property" as defined under
Section 101 of the Bankruptcy Code. The Parties agree that Licensee, as licensee
of such rights under this Agreement, shall retain and may fully exercise all of
its rights and elections under the Bankruptcy Code in the event of any
bankruptcy or insolvency proceeding of any kind or nature.
9.11 CUMULATIVE REMEDIES. The rights and remedies of the parties as set
forth in this Agreement are not exclusive and are in addition to any other
rights and remedies now or hereafter provided by law or at equity.
9.12 CAPTIONS AND HEADINGS. The captions and headings used in this
Agreement are inserted for convenience only, do not form a part of this
Agreement, and shall not be used in any way to construe or interpret this
Agreement.
8
CONFIDENTIAL
9.13 CONSTRUCTION. This Agreement has been negotiated by the parties
and shall be interpreted fairly in accordance with its terms and without any
construction in favor of or against any Party.
9.14 COUNTERPARTS. This Agreement may be executed (including, without
limitation, by facsimile signature) in one or more counterparts, with the same
effect as if the parties had signed the same document. Each counterpart so
executed shall be deemed to be an original, and all such counterparts shall be
construed together and shall constitute one Agreement.
9.15 ENTIRE AGREEMENT; AMENDMENT. This Agreement, including the
Exhibit(s) attached hereto which are incorporated herein by reference,
constitutes the entire understanding and only agreement between the parties with
respect to the subject matter hereof and supersedes any and all prior or
contemporaneous negotiations, representations, agreements and understandings,
written or oral, that the parties may have reached with respect to the subject
matter hereof (including, without limitation, that certain Deal Memorandum
between the parties dated January 6, 2004 by the signatories). No agreements
altering or supplementing the terms hereof may be made except by means of a
written document signed by the duly authorized representatives of each of the
parties hereto.
IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this Agreement as of the Effective Date.
--------------------------------------- ---------------------------------------
("Licensor") ("Licensee")
By: By: Xxxxx Xxxxxxx
-------------------------------- -------------------------------
Name: Name: /s/ Xxxxx Xxxxxxx
-------------------------------- -------------------------------
Title: Title: CEO
-------------------------------- -------------------------------
9
CONFIDENTIAL
EXHIBIT A
Part 1*
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1733-US Method And Treatment For Treating Psoriasis 08/535,705 5,836,999
Using Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX Method And Apparatus For Depilation Using 48174/96 717203
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1744-CA Method And Apparatus For Depilation Using 2,171,260
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-1744-DEU Depilation Using Radiation 29623504.0 296 23 504.0
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Denmark X-0000-XXX Xxxxxx and Apparatus for Depiliation Using DK9800173U DK9800173U
Pulsed Electromagnetic Radiation (BA1998 00173) (BA1998 00173)
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-1744-EP Method And Apparatus For Depilation Using 96301922.9
Office Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1744-JP Method And Apparatus For Depilation Using 77310/96
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1744-US Method And Apparatus For Depilation Using 08/412,519 5,683,380
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1744-US1 Method And Apparatus For Electromagnetic 08/912,764 6,280,438
Treatment Of The Skin, Including Hair
Depilation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1744-US2 Method And Apparatus For Electromagnetic 09/505,998 6,514,243
Treatment Of The Skin, Including Hair
Depilation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1744-US3 Method And Apparatus For Electromagnetic 10/246,722
Treatment Of The Skin, Including Hair
Depilation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX Method And Apparatus For Depilation Using 12295/97 729559
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1747-CA Method And Apparatus For Depilation Using 2,195,294
Pulsed Electronic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1747-JP Method And Apparatus For Depilation Using 25618/97
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1747-US Method And Apparatus For Depilation Using 08/605,321 5,885,273
Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1749-US Method And Apparatus For Diagnosis Of Skin 08/594,000 0000000
Lesions
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1753-US Method And Apparatus For Treatment Of Cancer 08/536,985 5,776,175
Using Pulsed Electromagnetic Radiation
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1755-CA Method And Apparatus For Skin Rejuvenation 2,185,196
And Wrinkle Smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-1755-EP Method And Apparatus For Skin Rejuvenation 96306588.3
Office And Wrinkle Smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1755-JP Method And Apparatus For Skin Rejuvenation 243696/96
And Wrinkle Smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
--------
* Lumenis makes no representation that the patents or applications listed in
Part 1 of this Exhibit A will be maintained.
10
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1755-US1 Method And Apparatus For Skin Rejuvination 08/529,044 5,964,749
And Wrinkle Smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 Method And Apparatus For Skin Rejuvination 09/307,874 6,387,089
And Wrinkle Smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1756-US Method And Apparatus For Therapeutic 08/508,129 5,720,772
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX Method And Apparatus For Therapeutic 43326/96 691713
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1758-CA Method And Apparatus For Therapeutic 2,093,055 2,093,055
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada X-0000-XX0 Xxxxxx And Apparatus For Therapeutic 2,168,624 2,168,624
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-1758-DE Apparatus And Method For Therapeutic 93302662.7 69329885.5
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Denmark P-1758-DK Apparatus And Method For Therapeutic 93302662.7 0565331
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-1758-EP Apparatus And Method For Therapeutic 93302662.7 0 565 331
Office Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent X-0000-XX0 Xxxxxx Apparatus For Therapeutic 96300756.2
Office Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-1758-EP2 Apparatus And Method For Therapeutic 00124370.8
Office Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-1758-EP3 Apparatus And Method For Therapeutic 00124371.6
Office Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Finland P-1758-FI1 Method And Apparatus For Therapeutic 960,493
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
France P-1758-FR Apparatus And Method For Therapeutic 93302662.7 0565331
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxxx X-0000-XX Apparatus And Method For Therapeutic 93302662.7 0565331
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Italy P-1758-IT Apparatus And Method For Therapeutic 93302662.7 0565331
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1758-JP Method And Apparatus For Therapeutic 18004/96
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1758-KR Apparatus For Therapeutic Electromagnetic 2667/1996
Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1758-US Apparatus And Method For Therapeutic 07/964,210 5,405,368
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 A System For Providing Pulsed Light To An 08/398,542 5,828,803
Optical Fiber
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1758-US2 Method And Apparatus For Therapeutic 08/473,532 5,755,751
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 Method And Apparatus For Therapeutic 08/992,319 6,174,325
Electromagnetic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 A System For Providing Pulsed Light To An 08/383,509 5,626,631
Optical Fiber
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 A System For Providing Pulsed Light To An 08/477,479 5,620,478
Optical Fiber
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1767-US Method And Apparatus For The Diagnostic And 08/385,190 5,643,334
Composite Pulsed Heating And Photodynamic
Therapy Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-2241-US Optimal procedure for performing a hair 09/294,753 6,162,212
removal
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
11
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-2809-US Method And Apparatus For An Efficient 08/394,238 5,707,401
Photodynamic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
European Patent P-4983-EP Flash Lamp Pulse Width Control 97304777.2
Office
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-4989-IL Skin Treatment Device With Incoherent Pulsed 101547 101547
Light Source
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Measurement of Burn Depth in Skin 5,074,306
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Use of Green Porphyrins to Treat 6,610,679
Neovasculature in the Eye
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/664,193
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/663,987
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 10/377,099
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 10/357,496
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/494,098
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
12
CONFIDENTIAL
Part 2*
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR HAIR TRANSPLANTATION 39099/95
USING A SCANNING CONTINUOUS-WORKING CO2 LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1004-CA METHOD AND APPARATUS FOR HAIR TRANSPLANTATION 2164157
USING A SCANNING CONTINUOUS-WORKING CO2 LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1004-EP METHOD AND APPARATUS FOR HAIR TRANSPLANTATION 95308595.8
USING A SCANNING CONTINUOUS WORKING CO2 LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1004-JP METHOD AND APPARATUS FOR HAIR TRANSPLANTATION HE1.7-335804
USING A SCANNING CONTINUOUS-WORKING CO2 LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1004-KR METHOD AND APPARATUS FOR HAIR TRANSPLANTION 95-45354
USING A SCANNING CONTINUOUS-WORKING CO2 LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-1008-GB HAIR REMOVAL WITH A LASER SYSTEM AND GB 9626150.8
WAVEGUIDE FOR RADIAL TRANSMISSION OF LASER
ENERGY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1008-IL HAIR REMOVAL WITH A LASER SYSTEM AND 119854
WAVEGUIDE FOR RADIAL TRANSMISSION OF LASER
ENERGY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1008-USP HAIR REMOVAL WITH A LASER SYSTEM AND 60/008,802
WAVEGUIDE FOR RADIAL TRANSMISSION OF LASER
ENERGY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1009-IL GAS LASER 95906 95,906
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1020-IL TRANSPARENT LASER HANDPIECE OPERATING TIP 121215
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX HAIR REMOVAL BY SELECTIVE PHOTOTHERMOLYSIS 10710/97 704,892
WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Brazil P-1036-BR HAIR REMOVAL BY SELECTIVE PHOTOTHERMOLYSIS PI 9612145-9
WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1036-CA HAIR REMOVAL BY SELECTIVE PHOTOTHERMOLYSIS 2240842
WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1036-IL NON-INVASIVE HAIR REMOVAL BY SELECTIVE 119051 119,051
PHOTOTHERMOLYSIS WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
----------
* Lumenis makes no representation, warranty or covenant that the patents or
applications listed in Part 2 of this Exhibit A are in force, or, if such
patents or applications are in force, that such patents or applications will be
maintained.
13
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1036-JP HAIR REMOVAL BY SELECTIVE PHOTOTHERMOLYSIS 9-513798
WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxx Xxxxxxx X-0000-XX HAIR REMOVAL BY SELECTIVE PHOTOTHERMOLYSIS 323705
WITH AN ALEXANDRITE LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1044-IL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX LASER FACIAL REJUVENATION 42155/96
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1053-CA LASER FACIAL REJUVENATION 2168276
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1053-EP LASER FACIAL REJUVENATION 96300692.9
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1053-JP LASER FACIAL REJUVENATION HEI.8-40657
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1053-KR LASER FACIAL REJUVENATION 96-2586
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX A SCANNING LASER INSTRUMENT FOR MYRINGOTOMY 08/370,267
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX LASER HEAD AND MICROSCOPE ATTACHMENT ASSEMBLE 07/179,819 4,856,512
WITH SWIVEL CAPABILITY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX GAS LASER 07/450,580 5,020,070
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX A LASER SYSTEM 09/032,393
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 A LASER SYSTEM 09/289,877
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1112-IL OPTICAL-FIBER TYPE POWER TRANSMISSION DEVICE 82163 82,163
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX OPTICAL-FIBER TYPE POWER TRANSMISSION DEVICE 136620 4,830,462
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1115-US METHOD AND APPARATUS FOR COMBINING TWO LOWER 317678 4,982,166
POWER LASER BEAMS TO PRODUCE A COMBINED
HIGHER POWER BEAM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1116-US METHOD AND APPARATUS FOR ATTENUATION AND 317575 5,004,338
MEASUREMENT OF LASER POWER AT THE END OF A
LASER GUIDE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX COMBINED ELECTROSURGERY AND LASER BEAM 371744 5,011,483
DELIVERY DEVICE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX ENDOSCOPIC ATTACHMENT TO A SURGICAL LASER 613338 4,597,380
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX LASER SYSTEM WITH LASER ACTUATION MEANS 264417 4,907,588
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1128-IL OPHTHALMOSCOPIC INSTRUMENT FOR MEASURING EYE 56509 56,509
DEFECTS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1146-IL METHOD AND APPARATUS FOR PERFORMING 120811
TRANSMYOCARDIAL REVASCULARIZATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1146-US METHOD AND APPARATUS FOR PERFORMING 09/075,293
TRANSMYOCARDIAL REVASCULARIZATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1147-IL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX DEVICE FOR TREATING TISSUE VOLUMES 30522/99
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1299-CA DEVICE FOR TREATING TISSUE VOLUMES 2325896
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
14
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1302-IL A SYSTEM FOR LAPAROSCOPIC ULTRASOUND GUIDANCE 121357
OF A SURGICAL CRYO-PROBE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1645-EP SYSTEM AND METHOD FOR MANIPULATING MOVEMENT 99926731.1
OF AN ENERGY EMITTING DEVICE WITHIN A BODY
CAVITY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1733-CA METHOD AND APPARATUS FOR TREATING PSORIASIS 2185197
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1733-EP METHOD AND APPARATUS FOR TREATING PSORIASIS 96306917.4
USING PULSED ELECTOMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1733-JP METHOD AND TREATMENT FOR TREATING PSORIASIS 254790/96
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1733-KR METHOD AND TREATMENT FOR TREATING PSORIASIS 43484/1996
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR CONTROLLING THE 76419/96
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1743-CA METHOD AND APPARATUS FOR CONTROLLING THE 2193193
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1743-EP METHOD AND APPARATUS FOR CONTROLLING THE 96309353.9
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1743-JP METHOD AND APPARATUS FOR CONTROLLING THE 347438/96
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1743-KR METHOD AND APPARATUS FOR CONTROLLING THE 72413/1996
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1743-US METHOD AND APPARATUS FOR CONTROLLING THE 08/578,754 5,849,029
THERMAL PROFILE OF SKIN
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Austria X-0000-XX XXXXX XXX ELEKTROMAGNETISCHEN THERAPIE AT1993000302662 AT198836T
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Finland P-1744-Fl METHOD AND APPARATUS FOR DEPILATION USING 961413
PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1744-KR METHOD AND APPARATUS FOR DEPILATION USING 8841/1996
PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1747-EP METHOD AND APPARATUS FOR DEPILATION USING 97300804.8
PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1747-KR METHOD AND APPARATUS FOR DEPILATION USING 3831/1997
PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR DIAGNOSIS OF SKIN 12296/97 707,237
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1749-CA METHOD AND APPARATUS FOR DIAGNOSIS OF SKIN 2195292
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
15
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1749-EP METHOD AND APPARATUS FOR DIAGNOSIS OF SKIN 97300806.3
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1749-JP METHOD AND APPARATUS FOR DIAGNOSIS OF SKIN 25586/97
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1749-KR METHOD AND APPARATUS FOR DIAGNOSIS OF SKIN 3830/1997
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR TREATMENT OF CANCER 64464/96 726,249
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Brazil P-1753-BR METHOD AND APPARATUS FOR TREATMENT OF CANCER PI 9603841-1
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1753-CA METHOD AND APPARATUS FOR TREATMENT OF CANCER 2187417
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1753-EP METHOD AND APPARATUS FOR TREATMENT OF CANCER 96306916.6
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1753-JP METHOD AND APPARATUS FOR TREATMENT OF CANCER 256706/96
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1753-KR METHOD AND APPARATUS FOR TREATMENT OF CANCER 43483/1996
USING PULSED ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX Method and apparatus for skin rejuvenation 64310/96 726267
and wrinkle smoothing
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1755-KR METHOD AND APPARATUS FOR SKIN REJUVINATION 39986/1996
AND WRINKLE SMOOTHING
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1755-US METHOD AND APPARATUS FOR SKIN REJUVINATION 08/529,044
AND WRINKLE SMOOTHING
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR THERAPEUTIC 60620/96 700,079
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1756-CA METHOD AND APPARATUS FOR THERAPEUTIC 2180616
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1756-EP METHOD AND APPARATUS FOR THERAPEUTIC 96305423.4
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1756-JP METHOD AND APPARATUS FOR THERAPEUTIC 197889/96
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1756-KR METHOD AND APPARATUS FOR THERAPEUTIC 31694/1996
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
16
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Finland P-1758-FI METHOD AND APPARATUS FOR THERAPEUTIC 931608
ELECTROMAGNETIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 44402/96
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1767-CA METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 2168636
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe I P-1767-EP METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 96300783.6
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Finland P-1767-Fl METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 960539
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1767-JP METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 21436/96
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1767-KR METHOD AND APPARTUS FOR THE DIAGNOSTIC AND 2790/1996
COMPOSITE PULSED HEATING AND PHOTODYNAMIC
THERAPY TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX MONITORING APPARATUS 33252/97 717,103
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1768-CA MONITORING APPARATUS 2212396
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1768-EP MONITORING APPARATUS 97114468.8
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1768-KR MONITORING APPARATUS 43560/1997
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1887-CA APPARATUS AND METHOD FOR VENOUS LIGATION 2181453
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1887-EP APPARATUS AND METHOD FOR VENOUS LIGATION 95908069.8
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1887-US3 APPARATUS AND METHOD FOR VENOUS LIGATION 08/183,994 5,437,664
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-1887-US4 IN SITU SAPHENOUS VEIN BYPASS APPARATUS WITH 08/646,776
CAUTERIZING ELECTRODE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX APPARATUS FOR IN-SITU CUTTING OF VALVES 07/366,427 5,026,383
WITHIN VEINS AND METHOD THEREFOR
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX HIGH POWER INFRARED LASER SYSTEM 25604/97
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-1931-CA HIGH POWER INFRARED LASER SYSTEM 2208280
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
17
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-1931-EP HIGH POWER INFRARED LASER SYSTEM 97110064.9
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-1931-IL HIGH POWER INFRARED LASER SYSTEM 121099
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-1931-JP HIGH POWER INFRARED LASER SYSTEM H9-162153
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-1931-KR HIGH POWER INFRARED LASER SYSTEM 97-25650
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX HIGH POWER INFRARED LASER SYSTEM 08/665,930 5,907,574
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2037-EP APPARATUS FOR THERAPEUTIC ELECTROMAGNETIC 98964564.3 1,042,033
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-2037-IL APPARATUS FOR THERAPEUTIC ELECTROMAGNETIC 136953
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-2037-US METHOD AND APPARATUS FOR HAIR REMOVAL USING 08/795,677
LONG PULSE OF ND: YAG LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 APPARATUS FOR THERAPEUTIC ELECTROMAGNETIC 08/997,398
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 METHOD METHOD OF OF INTRAVASCULAR -386517
ELECTROMAGNETIC RADIATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 APPARATUS FOR THERAPEUTIC ELECTROMAGNETIC 09/388,928
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2175-CA HOLLOW LIGHTPIPE AND METHOD FOR ITS 2,004,087-4 2,004,087
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-2175-DE HOLLOW LIGHTPIPE AND METHOD FOR ITS 37477
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2175-EP HOLLOW LIGHTPIPE AND METHOD FOR ITS 90/900557.1 451,169
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
France P-2175-FR HOLLOW LIGHTPIPE AND METHOD FOR ITS 90/900557.1 451,169
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-2175-GB HOLLOW LIGHTPIPE AND METHOD FOR ITS 90/900557.1 451,169
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Italy P-2175-IT HOLLOW LIGHTPIPE AND METHOD FOR ITS 90/900557.1 451,169
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2175-JP HOLLOW LIGHTPIPE AND METHOD FOR ITS 02-500773 02-500773
MANUFACTURE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Austria P-2266-AT LASER SCANNING METHOD AND APPARATUS 9091/96 9091/96
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2266-CA LASER SCANNING METHOD AND APPARATUS 2234669 2,234,669
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-2266-DE LASER SCANNING METHOD AND APPARATUS 19681641.6 19,681,642
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2266-EP LASER SCANNING METHOD AND APPARATUS 96940283.3
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-2266-GB LASER SCANNING METHOD AND APPARATUS 9808691.1 9808691.1
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2266-JP LASER SCANNING METHOD AND APPARATUS 9-517591
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2296-CA METHOD AND APPARATUS FOR HAIR REMOVAL 2222222
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2296-EP METHOD AND APPARATUS FOR HAIR REMOVAL 97905880.7
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
18
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2296-JP METHOD AND APPARATUS FOR HAIR REMOVAL 9-534384
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-2296-US1 METHOD AND APPARATUS FOR HAIR REMOVAL 08/858,420
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2297-CA METHOD AND APPARATUS FOR DERMATOLOGY TREATMENT 2224333 2,224,333
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2297-JP METHOD AND APPARATUS FOR DERMATOLOGY TREATMENT 9-505924
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-2638-US HOLLOW LIGHTPIPE USING A LOW REFRACTIVE INDEX 139285 4,805,987
INNER LAYER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 HOLLOW LIGHTPIPE AND LIGHTPIPE TIP USING A 07/310,774 5,005,944
LOW REFRACTIVE INDEX INNER LAYER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 LIGHTPIPE TIP FOR CONTACT LASER SURGERY 07/513,666 5,071,222
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2802-EP DEVICE AND METHOD FOR LASER MARKING 97929482.4
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2802-JP DEVICE AND METHOD FOR LASER MARKING H10-505429
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD FOR LASER SURGERY 19952/97
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2806-CA METHOD FOR LASER SURGERY 12201836
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-2806-IL METHOD FOR LASER SURGERY 120528
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-2806-JP METHOD FOR LASER SURGERY H9-113731
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) X-0000-XX XXXXXX FOR LASER SURGERY 97-18440
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxxxxx X-0000-XX METHOD AND APPARATUS FOR AN EFFICIENT 30650/95 696,682
PHOTODYNAMIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-2809-CA METHOD AND APPARATUS FOR AN EFFICIENT 2144209 2,144,209
PHOTODYNAMIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany X-0000-XX XXXXXX AND APPARATUS FOR AN EFFICIENT 19507980.9-33 19507980.9-09
PHOTODYNAMIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-2809-EP SYSTEM AND METHOD FOR ENDOSCOPICALLY APPLYING 98950947.6
AND MONITORING PHOTODYNAMIC THERAPY AND
PHOTODYNAMIC DIAGNOSIS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-2809-GB METHOD AND APPARATUS FOR AN EFFICIENT GB9504032.5 GB2287652
PHOTODYNAMIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-2809-IL METHOD AND APPARATUS FOR AN EFFICIENT 108918 108,918
PHOTODYNAMIC TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-2809-IL1 SYSTEM AND METHOD FOR ENDOSCOPICALLY APPLYING 135831
AND MONITORING PHOTODYNAMIC THERAPY AND
PHOTODYNAMIC DIAGNOSIS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
South Africa P-2809-SA Method and Apparatus for An Efficient 9501948
Photodynamic Treatment
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
19
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 SYSTEM AND METHOD FOR ENDOSCOPICALLY APPLYING 08/961,014
AND MONITORING PHOTODYNAMIC THERAPY AND
PHOTODYNAMIC DIAGNOSIS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 SYSTEM AND METHOD FOR ENDOSCOPICALLY APPLYING 09/664,920
AND MONITORING PHOTODYNAMIC THERAPY AND
PHOTODYNAMIC DIAGNOSIS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-2810-DE APPARATUS FOR THE PHOTODYNAMIC THERAPY 4244429.2
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-2810-IL APPARATUS FOR THE PHOTODYNAMIC THERAPY 100545 100,545
TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX DEPILATORY METHOD AND DEVICE 08/980,625
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX AN APPARATUS SYSTEM AND METHOD FOR 09/956,245
IDENTIFYING A TREATMENT TOOL WITHIN A
PATIENT'S BODY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-3794-US METHOD FOR DELIVERING ENERGY WITHIN 08/792,355 5,906,609
CONTINUOUS OUTLINE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
PCT P-3978-PC A LASER PROBE PCT/IL02/00373
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-4215-DE CONTACT LASER DELIVERY SYSTEM 69122279.7 69,122,280
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-4215-EP CONTACT LASER DELIVERY SYSTEM 91300960.1 441,606
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
France P-4215-FR CONTACT LASER DELIVERY SYSTEM 91300960.1 441,606
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-4215-GB CONTACT LASER DELIVERY SYSTEM 91300960.1 441,606
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany X-0000-XX XXXXXX AND APPARATUS FOR SUPPLYING PULSED 92309279.5 537,032
POWER TO AN OPHTHALMIC LASER SYSTEM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-4221-EP METHOD AND APPARATUS FOR SUPPLYING PULSED 92309279.5 537,032
POWER TO AN OPHTHALMIC LASER SYSTEM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
France P-4221-FR METHOD AND APPARATUS FOR OPHTHALMIC O AN 192309279.5 1,537,032
LASER SYSTEM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-4221-GB METHOD AND APPARATUS FOR SUPPLYING PULSED 92309279.5 537,032
POWER TO AN OPHTHALMIC LASER SYSTEM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-4221-JP METHOD AND APPARATUS FOR SUPPLYING PULSED 4-315500
POWER TO AN OPHTHALMIC LASER SYSTEM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX DUAL WAVELENGTH TREATMENT OF VASCULAR LESIONS 09/538,787
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX POWER MONITORING ARRANGEMENT FOR BROKEN FIBER 09/602,442
DETECTOR
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX SOLID-STATE LASER WITH PRISMATIC GAIN-REGION 09/492,025 6,373,866
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX LASER TREATMENT FOR REDUCING WRINKLES 09/738,523
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 FIBER MANAGEMENT PACKAGE 10/115,584
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
PCT P-4283-PC FREQUENCY DOUBLED ND:YAG LASER WITH YELLOW PCTIUS01/27727
LIGHT OUTPUT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
20
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX FREQUENCY DOUBLED ND:YAG LASER WITH YELLOW 09/655,535
LIGHT OUTPUT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX SCANNING LASER HANDPIECE WITH SHAPED OUTPUT 09/814,445
BEAM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-4294-GB APPARATUS FOR DELIVERING A DEFOCUSED LASER 92308978.3 536,951
BEAM HAVING A SHARP-EDGED CROSS-SECTION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
France P-4299-FR ISOTOPIC CO2 LASER AND METHOD OF USE FOR 90313893.1 437,955
MEDICAL TREATMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-4300-EP MEDICAL LASER DELIVERY SYSTEM WITH INTERNALLY 92307057.7 529,823
REFLECTING
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-4305-JP METHOD AND DEVICE FOR PRECONDITIONING A LASER 4-56978
HAVING A SOLID STATE GAIN MEDIUM
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-4306-JP SOLID STATE LASER WITH INTERLEAVED OUTPUT 37408
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada X-0000-XX XXXXXX XXXXXXXXX 000000 1,268,362
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX HOLLOW WAVEGUIDE 06/713,149 4,652,083
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 HOLLOW WAVEGUIDE HAVING PLURAL LAYER 06/713,150 4,688,893
DIELECTRIC
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-4320-IL ELECTRONICALLY PULSED LASER SYSTEM 96089 96,089
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-4320-JP ELECTRONICALLY PULSED LASER SYSTEM 2-290603
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-4322-US HIGH REPETITION RATE ERBIUM: YAG LASER FOR 09/592,324 6,395,000
TISSUE ABLATION
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 LIQUID CIRCULATION SYSTEM FOR COOLING A LASER 08/873,823 5,781,574
HEAD
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-4385-US METHOD AND APPARATUS FOR TREATING VASCULAR 08/355,512
LESIONS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX ANTI-ASTIGMATIC OPHTHALMIC CONTACT LENS FOR 08/183,530 5,548,352
USE IN PERFORMING LASER SURGERY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Xxxxxx Xxxxxx X-0000-XX0 SURGICAL LASER HANDPIECE FOR SLIT INCISIONS 08/338,412 5,454,808
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-914-IL SIDE-EMITTING OPTICAL FIBERS FOR LASERS 112087 112,087
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-916-IL METHOD AND APPARATUS FOR APPLYING LASER BEAMS 108059 108,059
TO A WORKING SURFACE, PARTICULARLY FOR
ABLATING TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-916-IL1 METHOD AND APPARATUS FOR APPLYING LASER BEAMS 116556 116,556
TO A WORKING SURFACE, PARTICULARLY FOR
ABLATING TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-916-US1 METHOD AND APPARATUS FOR APPLYING LASER BEAMS 08/700,351
TO A WORKING SURFACE, PARTICULARLY FOR
ABLATING TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-916-US3 METHOD AND APPARATUS FOR APPLYING LASER BEAMS 08/738,304
TO A WORKING SURFACE, PARTICULARLY FOR
ABLATING TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-918-DE ASSEMBLY FOR LASER APPARATUS 19650574.7
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
21
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-918-IL HANDPIECE ASSEMBLY FOR LASER APPARATUS 116266
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-918-US HANDPIECE ASSEMBLY FOR LASER APPARATUS 08/759,563 5,951,544
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-919-IL SIDE-EMITTING OPTICAL FIBERS FOR LASERS WITH 113674 113,674
ORIENTATION MARKINGS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-920-IL LASER BEAM DELIVERY METHOD AND SYSTEM 112108 112,108
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-922-IL PACKAGED OPTICAL FIBER 112089 112,089
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-922-US1 PACKAGED OPTICAL FIBER 08/839,197
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-924-GB DEVICE FOR TREATING THE INTERIOR OF BODY 95305456.6 717,965
CAVITIES WITH LASER ENERGY
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Italy P-924-IT ION FOR INTERIOR BOGY ST WITH LASER ENERGY 195305456.6 10,717,965
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-925-IL ADAPTOR ASSEMBLY FOR A FIBER CONNECTOR 103327 103,327
PARTICULARLY USEFUL IN LASER APPARATUS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-927-IL LASER BEAM DELIVERY SYSTEM 102083 102,083
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-927-US LASER BEAM DELIVERY SYSTEM 08/070,816 5,364,391
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-928-US1 SYSTEM FOR CAUSING ABLATION OF IRRADIATED 08/175,980 5,411,502
MATERIAL OF LIVING TISSUE WHILE NOT CAUSING
DAMAGE BELOW A PREDETERMINED
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-928-US4 SYSTEM FOR CAUSING ABLATION OF IRRADIATED 09/040 ,729
MATERIAL OF LIVING TISSUE WHILE NOT CAUSING
DAMAGE BELOW A PREDETERMINED
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-929-IL COUPLER DEVICE FOR LASER APPARATUS 100441 100,441
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-929-US COUPLER DEVICE FOR LASER APPARATUS 07/985,048
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-931-IL CONTROL APPARATUS PARTICULARLY USEFUL FOR 67599 67,599
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-934-IL HANDPIECE FOR LASER APPARATUS 105957
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-935-EP LASER MICROSCOPE ADAPTOR APPARATUS WITH AUTO 95304619
- FOCUS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-935-IL LASER MICROSCOPE ADAPTOR APPARATUS WITH 108335
AUTO-FOCUS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-935-US1 LASER MICROSCOPE ADAPTOR APPARATUS WITH 08/421,436 6,071,275
AUTO-FOCUS
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-936-EP METHOD AND APPARATUS FOR GENERATING BRIGHT 94307879
LIGHT SOURCES
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-936-IL METHOD AND APPARATUS FOR GENERATING BRIGHT 107299
LIGHT SOURCES
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-960-IL APPARATUS AND METHOD FOR TREATMENT EMPLOYING 1118229
A LASER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-964-US TONGUE BLADE EVACUATION SYSTEM 223986 5,460,626
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-965-IL FIBER SHAPER 121259
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
22
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-966-US SYNCRONIZATION OF LASER OPERATION AND SCANNER 08/834,024
MOVEMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-966-USP SYNCRONIZATION OF LASER OPERATION AND SCANNER 60/015,333
MOVEMENT
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Australia P-991-AU APPARATUS AND METHOD FOR LASER VAPORIZATION 68883/96
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Brazil P-991-BR APPARATUS AND METHOD FOR LASER VAPORIZATION PI 9610936-0 PCT/IL96/0009
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Canada P-991-CA APPARATUS AND METHOD FOR LASER VAPORIZATION 2231421
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-991-EP APPARATUS AND METHOD FOR LASER VAPORIZATION 96 929 502.1
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan P-991-JP APPARATUS AND METHOD FOR LASER VAPORIZATION 9-512541
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) P-991-KR APPARATUS AND METHOD FOR LASER VAPORIZATION 705545/1998
OF HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-991-US APPARATUS AND METHOD FOR LASER DRILLING OF 08/711,184
HARD TISSUE
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States P-991-USP VAPORIZATION AND LASER DRILLING OF HARD 60/003,361
TISSUE-TEETH AND BONES- WITH A CO2 LASER
FLASHSCANNER
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Germany P-993-DE APPARATUS AND METHOD AS PREPARATION FOR 196 80 710.7
PERFORMING A MYRINGOTOMY IN A CHILD'S EAR
WITHOUT NEED FOR ANAESTHESIA
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Great Britain P-993-GB APPARATUS AND METHOD AS PREPARATION FOR 9705008.2
PERFORMING A MYRINGOTOMY IN A CHILD'S EAR
WITHOUT NEED FOR ANAESTHESIA
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-993-IL APPARATUS AND METHOD AS PREPARATION FOR 120357
PERFORMING A MYRINGOTOMY IN A CHILD'S EAR
WITHOUT NEED FOR ANAESTHESIA
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe P-995-EP FOLDABLE FOOT SWITCH 96305800.3
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel P-995-IL FOLDABLE FOOT SWITCH 119013
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/007,417
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/684,839
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/684,839
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 119508
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Europe Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Japan Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Korea (South) Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/547,984
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/003,360
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
23
CONFIDENTIAL
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
COUNTRY EPLC ID FULL-TITLE APP. NO. REG. NO.
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/461,260
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/883,873
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/367,473
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/767,972
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 120347
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/383,724
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted -364251
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/134,213
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/263,761
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/262,669
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/106,584
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/214,027
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/227,363
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/121,265
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/443,034
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/526,149
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/276,713
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/478,728
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/765,183
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/815,467
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 09/439,919
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 112512
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 103664
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 100664
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 108060
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/358,420
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 120631
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
Israel Redacted Redacted 119210
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 08/711,425
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
United States Redacted Redacted 60/003,362
------------------- ----------------- ----------------------------------------------- ---------------- -----------------
24
CONFIDENTIAL
EXHIBIT B
LOS ANGELES ACTION STIPULATED DISMISSAL
1 XXXXXXXXXXXX XXXX & XXXXXXXXX
XXXXXX X. XXXXXXX (State Bar No. 85293)
2 XXXXX X. XXXXXX (State Bar No. 189527)
XXXXX X. XXX (State Bar No. 208107)
3 000 Xxxxx Xxxxxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxx, Xxxxxxxxxx 00000
4 Telephone: (000) 000-0000
Facsimile: (000) 000-0000
5
XXXXXXXXXXXX XXXX & XXXXXXXXX
6 XXXXXX X. XXXXXX (Admitted PRO HAC VICE)
0000 Xxxxx Xxxxx
0 Xxxxxxx, Xxxxxxxx 00000
8 Attorneys for Plaintiffs
LUMENIS LTD. and LUMENIS INC.
9
10 XXXXXXX X. XXXXXXXX (State Bar No. 133785)
XXXXXXX X. PRESS (State Bar No. 125027)
11 XXXXXXXX X. XXX (State Bar No. 193374)
XXXXXXXX & XXXXXXXX LLP
12 000 Xxxx Xxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxx, Xxxxxxxxxx 00000-0000
13 Telephone: (000) 000-0000
Facsimile: (000) 000-0000
14
Attorneys for Defendants
15 SYNERON INC. and
SYNERON MEDICAL LTD.
16
00 XXXXXX XXXXXX XXXXXXXX XXXXX
18 CENTRAL DISTRICT OF CALIFORNIA
19
20 LUMENIS LTD., an Israeli corporation; and Case No. 02-8269 ABC (PLAx)
LUMENIS INC., a Massachusetts
21 corporation,
22 Plaintiffs, STIPULATION RE: DISMISSAL
OF ACTION WITH PREJUDICE
23 v.
24 SYNERON MEDICAL LTD., an Israeli
corporation; SYNERON INC., a Delaware
25 corporation; SYNERON CANADA CORP.,
a Canadian corporation; and Does 1
26 through 10,
27 Defendants.
28
la-702051
25
CONFIDENTIAL
1 The parties, having reached a settlement of all claims that have been asserted
2 or could be asserted in this litigation,
3 HEREBY STIPULATE AND AGREE through their designated counsel and
4 pursuant to Federal Rules of Civil Procedure Rule 41(a)(1), that all claims asserted
5 in this action by plaintiffs Lumenis Ltd. and Lumenis Inc. are dismissed with
6 prejudice. Each party shall bear its own attorneys' fees and costs.
7
8 Dated: _________, 2004 XXXXXXXXXXXX XXXX & XXXXXXXXX
9
10 By:
--------------------------------
11 Attorneys for Plaintiffs
LUMENIS LTD. and LUMENIS INC. 12
13
14 Dated: _________, 2004 XXXXXXXX & XXXXXXXX LLP
15
16 By:
--------------------------------
17 Attorneys for Defendants
SYNERON INC. and SYNERON
18 MEDICAL LTD.
19
20
21
22
23
24
25
26
27
28
1
26
CONFIDENTIAL
EXHIBIT C
SANTA XXXXX ACTION STIPULATED DISMISSAL
--------------------------------------------------------------------------------
ATTORNEY OR PARTY WITHOUT
ATTORNEY (Name and Address): TELEPHONE NO.: FOR COURT USE ONLY
Xxxx X. Xxxxxx (SBN 52767) (000) 000-0000
XXXXXXXXXXXX XXXX & XXXXXXXXX LLP
000 Xxxx Xxxxxx
0xx Xxxxx
Xxx Xxxxxxxxx, XX 00000
Facsimile: (000)000-0000
ATTORNEY FOR (Name): Plaintiff and Cross-Defendant
Insert name of court and name of judicial district and branch court, if any:
Santa Xxxxx County Superior Court
Superior Court Old Courthouse
PLAINTIFF/PETITIONER: LUMENIS INC., a Massachussetts corporation
DEFENDANT/RESPONDENT: SYNERON, INC., a Delaware corporation, et al.
REQUEST FOR DISMISSAL CASE NUMBER:
Personal Injury, Property Damage, or Wrongful Death CV811282
Motor Vehicle Other
Family Law
Eminent Domain
X Other (specify): Breach of Contract, etc.
--- A conformed copy will not be returned by the clerk unless a method of return
is provided with the document. ---
--------------------------------------------------------------------------------
1. TO THE CLERK: Please dismiss this action as follows:
a. (1) X With prejudice (2) Without prejudice
b. (1) Complaint (2) Petition
(3) Cross-complaint filed by (name): on (date):
(4) Cross-complaint filed by (name): on (date):
(5) X Entire action of all parties and all causes
of action
(6) Other (specify):*
Date: January , 2004 Xxxxxxxxxxxx Xxxx & Xxxxxxxxx LLP
Xxxx X. Xxxxxx (SBN 52767)
--------------------------------------- ---------------------------------------
(TYPE OR PRINT NAME OF (SIGNATURE)
X ATTORNEY Attorney or party without attorney for:
PARTY WITHOUT ATTORNEY) Lumenis Inc.
*If dismissal requested is of specified X Plaintiff/Petitioner
parties only, of specified causues of Defendant/Respondent
action only, of specified cross Cross-complainant
complaints only, so state and identify
the parties, causes of action, or
cross-complaints to be dismissed.
27
CONFIDENTIAL
--------------------------------------------------------------------------------
2. TO THE CLERK: Consent to the above
dismissal is hereby given.**
Date: January , 2004 Fulbright S Xxxxxxxx
L.L.P.
Xxxxx X. Xxxxx (SBN 71839)
--------------------------------------- ---------------------------------------
(TYPE OR PRINT NAME OF (SIGNATURE)
X ATTORNEY Attorney or party without attorney for:
PARTY WITHOUT ATTORNEY Syneron, Inc., Xxxxx X. Xxxxxx,
J. Scott, Callihan, Xxxx Xxxxxxxx,
Xxxxxxx Xxxxxxxx and Xxxxx X. Xxxxxxxxx
**If a cross-complaint - or Response Plaintiff/Petitioner
(Family Law) seeking affirmative relief X Defendant/Respondent
- is on file, the attorney for cross- X Cross-complaints
complaint (respondent) must sign this
consent if required by Code of Civil
Procedure section 581(i) or (j).
--------------------------------------------------------------------------------
(To be completed by clerk)
3. Dismissal entered as requested on (date):
4. Dismissal entered on (date): as to only (name):
5. Dismissal not entered as requested for the following reasons (specify):
6. a. Attorney or party without attorney notified on (date):
b. Attorney or party without attorney not notified. Filing party failed
to provide a copy to conform means to return conformed copy
Date: Clerk, by , Deputy
---------------------------
--------------------------------------------------------------------------------
REQUEST FOR DISMISSAL
Form Adopted by the Judicial Council of California 982(a)(5)
[Rev. January 1, 1997] Mandatory Form
Legal Solutions Plus
Code of Civil Procedure,ss.581 et seq. Cal. Rules of Court, rules 383, 1233
28
CONFIDENTIAL
EXHIBIT D
ISRAEL ACTION STIPULATED DISMISSAL
Civil claim ____________
INTEL AVIV - JAFO
Scheduled For Pre-Trial 24.2.04 before
HIS HONOUR JUDGE XXX XXXX
CONCERNING: Lumenis Ltd.
Represented by Advocates X. Xxxxxxxxxxx and/or A.D. Pelossof
and/or X. Xxx-Tal From Xxxxxxxxxx Xxxxx, 00 Xxxxxxx Xx.
Xxx-Xxxx, 00000
Tel: 00-0000000 Fax: 00-0000000
PLAINTIFF
- Vs. -
1. Xxxxxx Xxxxxxxx I.D. 041785635
2. Syneron Medical Ltd. Company Number 512986514
3. Xxxxxxx Xxxxxxxx I.D. 311020762
4. Xxxx Xxxxxxxxxx I.D. 321274557
5. Xxxxx Xxxx I.D. 007776115
Represented By Xxxx Xxxxxx & Co., Advocates
Which their address for service of process is:
00 Xxxxxxx Xx. Xxx-Xxxx, 00000
Tel: 00-0000000 Fax: 00-0000000
DEFENDANTS
Announcement concerning a Settlement Agreement:
1. The parties hereby give notice to the honorable court that on
__________ a settlement agreement was signed between the Plaintiff and
Defendant 2, which makes redundant the continuation of process in this
claim.
2. Accordingly, the court is requested to dismiss the claim without writ
for expenses.
3. The Plaintiff undertakes not to file claim anywhere in world with
respect to the claims set forth in this claim.
4. Therefore, the parties request that the honorable court instruct to
dismiss the Claim as agreed and instruct that the court fees paid be
returned.
------------------------- --------------------------
Xxxx Xxxxxxxx, Advocate Xxx Xxx-Tal, Advocate
29
CONFIDENTIAL
EXHIBIT E
CONSENT AND ACKNOWLEDGEMENT
Lumenis Inc., a Massachusetts corporation with its principal place of
business in Santa Clara, California, and Lumenis Ltd., an Israeli corporation
with its principal place of business in Yokneam, Israel (together with their
parents, subsidiaries, affiliates, predecessors, permitted successors and
assigns, collectively "LUMENIS"), and [insert name], an individual residing in
[insert city], California, together with his assigns and heirs (collectively,
"SYNERON EMPLOYEE"), hereby agree as follows:
1. Each party has read and is familiar with the terms of Section 2 of the
Settlement Agreement by and between Lumenis, on the one hand, and Syneron, Inc.
and Syneron Medical Ltd., on the other ("SETTLEMENT AGREEMENT"). Capitalized
terms used and not otherwise defined herein shall the respective meanings
ascribed to such terms in the Settlement Agreement.
2. Each party acknowledges and agrees that Syneron Employee is an "employee"
of "Syneron" as those terms are used in Section 2 of the Settlement Agreement,
and acknowledges and agrees that Syneron Employee releases Lumenis and each of
its Commercial Partners, and Lumenis and its Associated Parties each releases
Syneron Employee, to the full extent provided in Section 2 of the Settlement
Agreement. Syneron Employee acknowledges and agrees that it shall not receive
any value or consideration from Lumenis in exchange for the releases provided
herein, separate from the consideration provided by Lumenis under the Settlement
Agreement.
3. Each party hereby irrevocably and forever waives all rights it may have
arising under California Civil Code Section 1542 (or any analogous requirement
of law) with respect to the releases. Each Party understands that Section 1542
provides that:
A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at
the time of executing the release, which if known by him
must have materially affected his settlement with the
debtor.
Each party acknowledges that it has been fully informed by its counsel
concerning the effect and import of this Consent and Acknowledgement, including
under California Civil Code Section 1542 and other requirements of law.
4. This Consent and Acknowledgement is entered into in order to compromise and
settle disputed claims, without any concession, admission, or acquiescence on
the part of any party as to the merit of any claim, defense, affirmative
30
CONFIDENTIAL
defense, counterclaim, liabilities or damages. This Consent and Acknowledgement,
the Settlement Agreement, and any part of either shall not be, or be used as, an
admission of liability by anyone, at any time, for any purpose.
5. Attorneys' Fees and Costs. Each party shall be responsible for its own
attorneys' fees and costs in connection with this Consent and Acknowledgement
and the pending litigation between the parties.
IN WITNESS WHEREOF, this Consent and Acknowledgement has been signed by and on
behalf of Lumenis and Syneron Employee, this _____ day of _______ 2004, and
shall be effective immediately.
Lumenis Ltd.
By:
----------------------------
Name:
----------------------------
Its:
----------------------------
Lumenis Inc.
By:
----------------------------
Name:
----------------------------
Its:
----------------------------
[insert name]
---------------------------------
31
CONFIDENTIAL
EXHIBIT F
LUMENIS COMPETITORS
Palomar Medical Technologies, Inc.
Danish Dermatological Development A/S
Altus Medical, Inc./Cutera, Inc.
Alderm, N.A. LLC
Candela Corporation
Cynosure Inc.
Laserscope Inc.
BIOLASE Technology, Inc.
Biolitec AG
Radiancy Ltd.
Primary Technologies
WaveLight Laser Technologie AG
